Risk of study-defined symptomatic intracranial haemorrhage after acute ischaemic stroke reperfusion therapy in heart failure
| Cardiac condition Reference name (number) (sICH timing) | Reperfusion type | Effect estimate (95% CI)* |
| Heart failure | ||
| Heart failureversusno heartfailure | ||
| Siedler et al, 201918 (<24 hours) | Intravenous rtPA and/or ET | Rate 15%versus20% |
| Abdul-Rahim et al, 201419 (<7 days) | Intravenous rtPA | OR 1.16 (0.37 to 3.66) |
| Schnieder et al, 201940 (22–36 hours) | ET | Rate 4.4% versus 1% |
| Based on LVEF | ||
| Siedler et al, 201918 (<24 hours) | ||
| 40%–50% | Intravenous rtPA and/or ET | Rate 6% |
| 25%–35% | Intravenous rtPA and/or ET | Rate 0% |
| <25% | Intravenous rtPA and/or ET | Rate 0% |
*CIs were not reported for all studies.
ET, endovascular therapy; LVEF, left ventricular ejection fraction; rate, rate of sICH in %; rtPA, tissue plasminogen activator.